Home > Prolactin Receptor, rat recombinant
Search results for: Prolactin Receptor, rat recombinant
#31838975 2019/12/16 To Up
PLF-1 (Proliferin-1) Modulates Smooth Muscle Cell Proliferation and Development of Experimental Intimal Hyperplasia.Background Although apoptosis and cell proliferation have been extensively investigated in atherosclerosis and restenosis postinjury, the communication between these 2 cellular events has not been evaluated. Here, we report an inextricable communicative link between apoptosis and smooth muscle cell proliferation in the promotion of vascular remodeling postinjury. Methods and Results Cathepsin K-mediated caspase-8 maturation is a key initial step for oxidative stress-induced smooth muscle cell apoptosis. Apoptotic cells generate a potential growth-stimulating signal to facilitate cellular mass changes in response to injury. One downstream mediator that cathepsin K regulates is PLF-1 (proliferin-1), which can potently stimulate growth of surviving neighboring smooth muscle cells through activation of PI3K/Akt/p38MAPK (phosphatidylinositol 3-kinase/protein kinase B/p38 mitogen-activated protein kinase)-dependent and -independent mTOR (mammalian target of rapamycin) signaling cascades. We observed that cathepsin K deficiency substantially mitigated neointimal hyperplasia by reduction of Toll-like receptor-2/caspase-8-mediated PLF-1 expression. Interestingly, PLF-1 blocking, with its neutralizing antibody, suppressed neointima formation and remodeling in response to injury in wild-type mice. Contrarily, administration of recombinant mouse PLF-1 accelerated injury-induced vascular actions. Conclusions This is the first study detailing PLF-1 as a communicator between apoptosis and proliferation during injury-related vascular remodeling and neointimal hyperplasia. These data suggested that apoptosis-driven expression of PLF-1 is thus a novel target for treatment of apoptosis-based hyperproliferative disorders.
Lina Hu, Zhe Huang, Hideki Ishii, Hongxian Wu, Susumu Suzuki, Aiko Inoue, Weon Kim, Haiying Jiang, Xiang Li, Enbo Zhu, Limei Piao, Guangxian Zhao, Yanna Lei, Kenji Okumura, Guo-Ping Shi, Toyoaki Murohara, Masafumi Kuzuya, Xian Wu Cheng
1119 related Products with: PLF-1 (Proliferin-1) Modulates Smooth Muscle Cell Proliferation and Development of Experimental Intimal Hyperplasia.100ul100ul100ul100ul100ul100ul100ul 100ul100ul100ul100ul
#31091528 2019/05/15 To Up
Vasoinhibin Suppresses Nerve Growth Factor-Induced Differentiation and Survival of PC12 Pheochromocytoma Cells.Vasoinhibin, a protein derived from prolactin, regulates various vascular functions including endothelial cell survival. Of note, vasoinhibin is present in the central nervous system, where it triggers neuroendocrine and behavioral responses to stress. Moreover, vasoinhibin compromises nerve growth factor (NGF)-induced neurite outgrowth in primary sensory neurons of the peripheral nervous system. Nonetheless, information on the functions of vasoinhibin in developing neurons remains limited. The present study explored whether vasoinhibin affects the neurotrophic actions of NGF by measuring the cell differentiation and survival of PC12 pheochromocytoma cells.
Zesergio Melo, Ximena Castillo, Bibiana Moreno-Carranza, MarÃa G Ledesma-Colunga, Edith Arnold, Fernando LÃ³pez-Casillas, Xarubet RuÃz-Herrera, Carmen Clapp, Gonzalo MartÃnez de la Escalera
2459 related Products with: Vasoinhibin Suppresses Nerve Growth Factor-Induced Differentiation and Survival of PC12 Pheochromocytoma Cells.5 x 50 ug50 ug5ug10 20 ug10ug1 mg5ug20 ug5ug5ug1
#31063493 2019/05/07 To Up
An in vivo half-life extended prolactin receptor antagonist can prevent STAT5 phosphorylation.Increasing evidence suggests that signaling through the prolactin/prolactin receptor axis is important for stimulation the growth of many cancers including glioblastoma multiforme, breast and ovarian carcinoma. Efficient inhibitors of signaling have previously been developed but their applicability as cancer drugs is limited by the short in vivo half-life. In this study, we show that a fusion protein, consisting of the prolactin receptor antagonist PrlRA and an albumin binding domain for half-life extension can be expressed as inclusion bodies in Escherichia coli and efficiently refolded and purified to homogeneity. The fusion protein was found to have strong affinity for the two intended targets: the prolactin receptor (KD = 2.3Â±0.2 nM) and mouse serum albumin (KD = 0.38Â±0.01 nM). Further investigation showed that it could efficiently prevent prolactin mediated phosphorylation of STAT5 at 100 nM concentration and above, similar to the PrlRA itself, suggesting a potential as drug for cancer therapy in the future. Complexion with HSA weakened the affinity for the receptor to 21Â±3 nM, however the ability to prevent phosphorylation of STAT5 was still prominent. Injection into rats showed a 100-fold higher concentration in blood after 24 h compared to PrlRA itself.
Shengze Yu, Amira Alkharusi, Gunnar Norstedt, TorbjÃ¶rn GrÃ¤slund
2669 related Products with: An in vivo half-life extended prolactin receptor antagonist can prevent STAT5 phosphorylation.2 Pieces/Box2 Pieces/Box2 Pieces/Box2 Pieces/Box2 Pieces/Box100 μg100 μg100ug
#28571011 2017/06/02 To Up
Vasoinhibin Suppresses the Neurotrophic Effects of VEGF and NGF in Newborn Rat Primary Sensory Neurons.Studies on the biological actions of vasoinhibins have focused mainly on endothelial cells. However, there is incipient knowledge about how vasoinhibins affect the nervous system, even if the target cells and mechanisms of action involved in these effects are unknown.
Ximena Castillo, Zesergio Melo, Alfredo Varela-EchavarrÃa, Elisa Tamariz, Rodrigo M AroÃ±a, Edith Arnold, Carmen Clapp, Gonzalo MartÃnez de la Escalera